Inactive Instrument

Oncorus, Inc.

Equities

ONCR

US68236R1032

Biotechnology & Medical Research

Oncorus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 09, 2022 at 06:16 pm IST

Oncorus, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 64.76 million compared to USD 48.3 million a year ago. Basic loss per share from continuing operations was USD 2.56 compared to USD 9.35 a year ago.

Latest news about Oncorus, Inc.

North American Morning Briefing : Fed Seen Holding Rates, Powell Comments Key	20/23/20	DJ
North American Morning Briefing : Inflation -2-	06/23/06	DJ
North American Morning Briefing : Stock Futures -2-	30/23/30	DJ
North American Morning Briefing : Nvidia Results -2-	23/23/23	DJ
North American Morning Briefing : Stock Futures -2-	16/23/16	DJ
North American Morning Briefing : Traders Absorb -2-	09/23/09	DJ
Oncorus, Inc. Announces Executive Changes	04/23/04	CI
Oncorus, Inc. Announces Changes to Its Board	04/23/04	CI
Oncorus, Inc. Announces Executive Changes	04/23/04	CI
Oncorus, Inc. Announces Board Changes	29/23/29	CI
Oncorus, Inc. Announces Resignation of Douglas M. Fambrough III from its Board of Directors as Well as Compensation Committee, Effective July 20, 2023	20/23/20	CI
Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC	20/23/20	CI
Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index	23/23/23	CI
Oncorus, Inc.(OTCPK:ONCR) dropped from NASDAQ Composite Index	20/23/20	CI
Oncorus Announces Management Changes	08/23/08	CI
Oncorus Appoints Brian Shea as Interim Chief Executive Officer	08/23/08	CI
Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday	02/23/02	MT
North American Morning Briefing : Stock Futures Rise as Jobs Report Swings Into Focus	02/23/02	DJ
Oncorus to Lay Off Almost Entire Workforce -- Shares Slump After-Hours	02/23/02	MT
Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus	02/23/02	DJ
Oncorus, Inc. Announces Workforce Reduction Plan	02/23/02	CI
Theodore Ashburn, Chief Executive Officer Departs from the Oncorus, Inc, Effective to Be No Later Than June 30, 2023	02/23/02	CI
Oncorus, Inc. Announces Management Changes, Effective to Be No Later Than June 30, 2023	02/23/02	CI
Oncorus, Inc. Contemplates Bankruptcy	01/23/01	CI
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI

Chart Oncorus, Inc.

Duration

Period

More charts

Company Profile

Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs